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We have investigated the signaling properties of the fibroblast growth factor (FGF) receptor substrate 3 (FRS3), also known as SNT-2 or
FRS2β, in neurotrophin-dependent differentiation in comparison with the related adapter FRS2 (SNT1 or FRS2α). We demonstrate that FRS3
binds all neurotrophin Trk receptor tyrosine kinases and becomes tyrosine phosphorylated in response to NGF, BDNF, NT-3 and FGF stimulation
in transfected cells and/or primary cortical neurons. Second, the signaling molecules Grb2 and Shp2 bind FRS3 at consensus sites that are highly
conserved among FRS family members and that Shp2, in turn, becomes tyrosine phosphorylated. While FRS3 over-expression in PC12 cells
neither increases NGF-induced neuritogenesis nor activation of Map kinase/AKT, comparable to previous reports on FRS2, over-expression of a
chimeric adapter containing the PH/PTB domains of the insulin receptor substrate (IRS) 2, in place of the PTB domain of FRS3 (IRS2-FRS3)
supports insulin-dependent Map kinase activation and neurite outgrowth in PC12 cells. Collectively, these data demonstrate that FRS3 supports
ligand-induced Map kinase activation and that the chimeric IRS2-FRS3 adapter is stimulating sufficient levels of activated MapK to support
neurite outgrowth in PC12 cells.
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doi:10.1016/j.bbamcr.2006.02.009differentiation of specific neuronal populations in the develop-
ing and mature nervous system [1–3]. Two distinct families of
cell surface receptors mediate these cellular effects: the p75
neurotrophin receptor and the Trk family of receptor tyrosine
kinases (RTKs). While p75 regulates a variety of cellular
responses such as apoptosis, myelination and neurite outgrowth
[4,5], the Trks, including TrkA (which binds NGF and NT-3),
TrkB (which binds BDNF and NT-4/5) and TrkC (which binds
NT-3), regulate signaling events underlying neuronal survival,
proliferation, differentiation as well as a variety of physiological
properties in the developing and adult nervous systems [1,6,7].
How Trk RTKs integrate and propagate neurotrophic signals
at the molecular level has been a topic of intensive study.
Available evidence indicates that Trks conform to a standard
model of RTK activation and signal transmission. In this model,
dimerization of RTK monomers and subsequent trans-phos-
phorylation of multiple intracellular tyrosine residues stabilizes
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binding sites which enable the direct recruitment of intracellular
proteins containing SH2 or PTB domains [8]. In turn, these
proteins orchestrate signaling events by activating various
intracellular signaling cascades [9].
Many different SH2 and PTB domain containing proteins
have been shown to bind directly to Trk receptors and to
participate in neurotrophic signal transduction (reviewed in refs.
[1,10]. Of these proteins, the PTB domain containing adapter
protein FRS2 has emerged as an important mediator of
neurotrophic signaling [11]. In PC12 cells [12], NGF-dependent
neurite extension is not observed in the absence of FRS2
tyrosine phosphorylation [11,13]. Moreover, a direct link
between FRS2 and neurite outgrowth in PC12 cells was
shown by replacement of the native PTB domain with that of the
insulin receptor substrate-1. Expression of this chimerical
protein in PC12 cells was sufficient to convert insulin from a
mitogenic to a differentiative agent [14]. Finally, a TrkA mutant
showing a decreased ability to bind FRS2 is defective in its
ability to drive neurite outgrowth, however, FRS2 over-
expression in cells expressing this mutant can reconstitute
NGF-dependent cell cycle arrest and differentiation [15]. These
results suggest that FRS2 activation is sufficient to organize/
scaffold the signaling events required for NGF-dependent
mitotic arrest and neuronal differentiation in vitro.
A second member of the FRS adapter protein family also
exists, namely FRS3, or FRS2β [16]. These two proteins share a
similar structural architecture overall, but initially appear to be
quite divergent, sharing only 48% amino acid sequence identity
and occupying separate chromosomal loci [17]. Analysis of the
expression patterns of FRS2 and FRS3 during embryonic
development reveals that FRS3 is expressed predominantly in
developing neuroepithelium while FRS2 is expressed in
multiple tissues [18,19].
Several lines of evidence, however, suggest overlapping
functions of FRS2 and FRS3 in mediating cellular responses. A
high degree of sequence identity lies within the N-terminal PTB
domain (74%) and the C-terminal 30 residues (86%; [17]. A
comparison of human, mouse and Xenopus FRS2 and FRS3
reveals five conserved sequence motifs (Fig. 1A) [17]: (1) an N-
terminal (MGXXXS) myristylation site required for plasma
membrane targeting, (2) an N-terminal phosphotyrosine binding
(PTB) domain that is involved in RTK binding [11,20], (3) three
(in FRS3) or 4 (in FRS2) consensus (p)Y–X–N, Grb2–SH2
domain binding sites, (4) two consensus (p)Y–I/V–X–V/I/L/P,
Shp2–SH2 domain binding sites and (5) the C-terminal 30
amino acids which, in FRS2, is important in SOS recruitment
and long-term MAPK/ERK activation [14]. Like FRS2, FRS3
binds both the FGF and Trk receptors [16,21] and ectopic
expression of FRS3 in FRS2 null fibroblasts reconstitutes MAP
kinase activation by FGF [19]. Finally, both FRS2 and FRS3
bind the small GTPase Rnd1, which is involved in the
suppression of Rho activity in FGF activated PC12 cells [22].
With the exception of a recent study detailing the binding of
FRS3 to the small GTPase Rnd1 [22] little attention has been
paid to the signaling properties of FRS3. Interestingly, Rnd1
binds the carboxyl-terminal region of both FRS2 and FRS3 andis dissociated in response to FGF-dependent Shp2 recruitment
[22]. Since siRNA-mediated knockdown of Rnd1 in PC12 cells
negated the positive effect of FGF on neurite outgrowth [22],
the authors conclude that one function of FRS3 is that of a
cytoplasmic anchor for Rnd1, and upon phosphorylation by the
FGFR1 exchanges Rnd1 for Shp2 allowing for the suppression
of Rho by Rnd1 [22]. Despite the compelling nature of these
results, the siRNA data in PC12 cells fails to differentiate
between FRS2 and FRS3. In this study, we further clarify the
role of FRS3 in neurotrophic signal transduction. We demon-
strate that FRS3 binds TrkA at pTyr499 and is a substrate of the
Trk kinase. Tyrosine-phosphorylated FRS3 recruits both Grb2
and Shp2 and recruitment of these proteins are absolute re-
quirements for the induction of neurite outgrowth in PC12 cells.
Unlike FRS2 [20], however, over-expression of FRS3 in PC12
cells does not enhance NGF-induced MAPK/ERK and/or AKT
phosphorylation above levels observed in controls. Conse-
quently, FRS3 over-expression in PC12 cells does not enhance
NGF-induced neuritogenesis compared to NGF-treated PC12
cells alone. Lastly, we demonstrate that FRS2 and FRS3 show
differential binding of the cell cycle regulators Cks1 and Cks2.
2. Materials and methods
2.1. Reagents
All reagents were from Bio-Shop and Sigma unless otherwise indicated. All
PCR reactions utilized either Platinum Taq (Invitrogen) or Pfu Ultra
(Stratagene). Tissue culture media (DMEM and Neurobasal) and antibiotics
were from Invitrogen Inc. and Wisent, respectively. NGF, EGF and FGF-2 were
from Harlan Bioproducts for Science. BDNF and NT-3 were the gifts of A.A.
Welcher (Amgen Inc.). The Dc protein assay kit was from Bio-Rad.
2.2. Antibodies
HRP conjugated anti-phosphotyrosine (RC20) and anti-Gal4 DNA Binding
Domain (DBD) mouse monoclonal antibodies were from Transduction Labs and
Santa Cruz Inc., respectively. Mouse anti-active-MAPK/ERK (BD-Bioscience),
mouse anti-HA 3F10 (Roche Applied Science), rabbit anti-phosphoAKT
(Ser473), AKT and MAPK/ERK antibodies (Cell Signaling Technology) and
rabbit anti-Grb2 and Shp2 antibodies (Santa Cruz Inc) were used as
recommended. Rabbit anti-Trk (A786LAQAPPSYLDVLG799) and rabbit anti-
FRS3 peptide (P361DGEEDETPLQKPTS375; G1466) antibodies were generated
(GeneMed Synthesis) and affinity purified using standard techniques. The anti-
myc mouse monoclonal antibody (9E10) [23] was purified from ascites tumors
grown in 4–6 weeks old Balb/c mice. HRP labeled secondary antibodies were
from Jackson Immunoresearch.
2.3. Constructs
(i) FRS3 isolation: Human FRS3 was isolated from a fetal brain cDNA
library (CLONTECH) using primers derived from the published SNT-2
sequence [16] that incorporated 5′ NcoI and 3′ SalI sites. A 1.5 kb PCR
product was isolated and cloned into pCR2.1 (Invitrogen Inc.) to generate
pCR2.1-hFRS3. (ii) Yeast-two Hybrid Vectors: Full-length FRS3 was subcloned
from pCR2.1-hFRS3 into the EcoRI and SalI sites of pGEX-4T1 and then into
the EcoRI and SalI sites of pGAD424 (CLONTECH) to generate pGAD424-
hFRS3. hFRS2 was subcloned from pCR2.1-hFRS2 [11], using the EcoRI and
SalI sites, into pGAD424 and via the NcoI and SalI sites into pAS2.1. pAS2.1-
rat TrkA ICD, rat TrkB ICD and rat TrkC ICD were constructed as described
[24]. The pAS2.1-TrkA ICD -S3, -S8, -S9 and -S11B constructs have previously
been described [13]. The S. pombe cell cycle regulatory gene, p13, was cloned as
an EcoRI–BamHI fragment into pGAD424 and Cks1/Cks2 were amplified from
Fig. 1. FRS3 binds the Trk receptors. (A) Schematic of FRS3. (B) The yeast two-hybrid system was used to examine the interaction between FRS3 and Trk. Yeast
(AH109) were co-transformed with the indicated constructs and first plated onto –LT plates. After 4–5 days, colonies were replica plated onto –HALT plates
containing 15 mM 3-AT. Full-length FRS3 and FRS2 (in pGAD424) were assayed for binding to the intracellular domains of rat TrkA, TrkB and TrkC (in pAS2.1). (C)
Schematic of TrkA intracellular domain (ICD) mutants. (D) Full-length FRS3 and FRS2 were assayed for binding to wild-type TrkA, TrkA S3 (ΔIMENP deletion),
TrkA S8 (Y499F), TrkA S9 (Y794F) and TrkA S11b (kinase dead). Empty pGAD424 and pAS2.1 vectors were used as negative controls in both experiments. (E) Yeast
cell lysates were assayed for tyrosine phosphorylation/expression of the TrkA mutants, by Western blotting, using anti-pTyr antibodies (1:2500) and anti GAL4-DNA
binding domain (DBD) antibodies (1:5000). Arrows indicate the position of the TrkA mutant-GAL4-DBD chimeras.
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For in vitro pull down experiments, p13, Cks1 and Cks2 were cloned into the
EcoRI/XhoI sites of pGEX-4T1. (iii) Expression vectors: MycHis tagged FRS3
was generated by PCR using 3′ primers incorporating a SalI site and deleting the
termination codon. The 1.5-kb fragment was cloned into pCR2.1 to give
pCR2.1-hFRS3ns (no stop) and then subcloned into the EcoRI and XhoI sites of
pcDNA-MycHisA (Invitrogen Inc.) to generate pcDNA3.1–MycHisA–hFRS3.
To create pcDNA3.1–MycHisC–FRS3–PTB domain, a 250-bp fragment
encompassing the FRS3–PTB domain (a.a.1–79) was isolated from pCR2.1–hFRS3 using EcoRI and XhoI and sub-cloned into the EcoRI–XhoI sites of
pcDNA3.1–MycHisC. (iv) FRS3 Point Mutations: Tyrosine to Alanine point
mutation constructs were generated using the overlap extension mutagenesis
procedure. PCR products (1.5 kb) were first TA cloned into pGEMT-EASY
(Promega), digested with EcoRI/SalI and ligated into the EcoRI and XhoI sites
of pcDNA3.1–MycHisA. FRS3 constructs for generating stable cell lines: the
pBig3i bi-directional expression vector [25] was used in this study. pBig3i–
hFRS3–MycHis was constructed by digesting the hFRS3–MycHis coding
sequence, including the start and stop codons, from pcDNA3.1–MycHisA–
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of pBig3i. All Trk constructs were in the vector pCMX.
The IRS2FRS2, IRS2FRS3 and IRS2FRS3-2A and 3A fusion proteins were
constructed similarly to that described previously [14]. A murine IRS2 fragment
encompassing the plekstrin homology (PH) and PTB domains (M1–G307) was
amplified from a mouse fetal brain cDNA library (Clontech) and cloned into
pcDNA 3.1 Myc/His. The C-terminal domains of FRS2 and FRS3 (amino acids
T138–S503 and P137–L492 for FRS2 and FRS3, respectively), excluding the
amino terminal PTB domains, were amplified by PCR and inserted in-frame
with the IRS2 PH and PTB domains and the C-terminal myc tag. For both fusion
proteins, the FRS portion was fused to the IRS2 region through an RP linkage.
Chimerical proteins were targeted to the membrane by incorporating the K-ras
C-terminal membrane targeting sequence KDGKKKKKKSRTRCTVM [26] C-
terminal to the myc tag [16]. A control vector contained only the PTB and PH
domains of the IRS2 fused to the K-ras targeting sequence. For FRS2 and FRS3
PTB domain swapping, the amino terminus of each protein (M1–T137 for FRS2
and M1–P137 for FRS3) was amplified by PCR and ligated into either FRS2 or
FRS3 carboxyl region from the IRS2 chimera's to produce FRS2(PTB)FRS3
and FRS3(PTB)FRS2 chimerical proteins. All PCR-based constructs were
verified by sequencing.
For baculovirus expression, myc-tagged FRS2 and FRS3 were excised from
the pcDNA vectors using EcoRI/PmeI and ligated into the EcoRI/SmaI sites of
pBacPAK 8 (Clontech). Both constructs retained the C-terminal myc tag. The
IRS2FRS2 and IRS2FRS3 chimeric proteins were excised from the pcDNA
vectors with HindIII/PmeI and cloned into the HindIII/EcorV sites of
pBluescript KSII. Following this, IRS2FRS2 was cut with XhoI and EcoRI
and IRS2FRS3 with SalI and EcoRI and cloned into the XhoI/EcoRI sites of
pBacPACK 8. Recombinant baculoviruses were generated with BacPACK6
viral DNA as described (Clontech) in T. ni (High Five, Clontech) insect cells.
2.4. Cell lines
Unless stated in the text, PC12, nnr5 and their derivative cell lines were
maintained as previously described [13]. High Five insect cells were maintained
in Grace's complete media containing 10% fetal bovine serum.
2.5. Cortical neurons
Cortical neurons were isolated from embryonic day 15 (E15) CD1 mice
using a standard procedure with minor modifications as previously described
[24]. Purified cortical neurons were plated onto 60 mm dishes (3×106 cell/each)
pre-coated with 100 mg/ml poly-D-Lysine (Sigma) and were kept in culture for
about 4 days. The medium was changed every 2 days. One hour prior to cell
harvest, endogenous neurotrophins were removed by washing twice with HBSS.
After stimulation with medium alone or NGF, BDNF, NT-3, EGF or bFGF
(100 ng/ml, 5 min), cells were washed with cold phosphate-buffered saline
containing 1 mM sodium orthovanadate and then lysed in ice-cold NP40 lysis
buffer containing 1 mM sodium orthovanadate as described above.
2.6. Generation of PC12-FRS3 cell lines
PC12 cell lines stably expressing a reverse tetracycline Trans-Activator
(rtTA)-FRS3 cassette were generated using the pBig3i vector [25].
Lipofectamine 2000 was the transfection vehicle and the cells were selected
in 0.3 mg/ml hygromycin. Forty-eight clones were isolated and assayed for
Doxycycline induced (2 μg/ml; 48 h) FRS3 expression by Western blotting
using the anti-myc (9E10) antibody. Twelve independent lines were identified,
three of which (FRS3-23, FRS3-27, and FRS3-48) were selected for further
characterization due to the tight Dox-induced regulation of FRS3 expression.
2.7. Yeast two-hybrid
The AH109 yeast strain (CLONTECH) was used for all experiments. Yeast
were co-transformed using the S.C. EasyComp kit (Invitrogen Inc.) following
the manufacturer's instructions and plated onto –Leu /–Trp (–LT) plates to
select for plasmid acquisition. Colonies were selected and re-plated onto –His /
–Ade /–Leu /–Trp (–HALT) plates to select for positive interactions. Self-activation was eliminated by the addition of 3-amino triazole (10–20 mM).
Yeast lysates were generated from 2 ml overnight liquid cultures (–LT).
Resuspended cell pellets in 1× SDS-PAGE sample buffer with 100 mM DTT
were subject to three cycles of freeze–thaw followed by boiling. Debris was
removed by centrifugation and expressed proteins assessed by SDS-PAGE.
2.8. Cell transfection, lysis, and protein concentration determination
COS-7 cells were transfected using the DEAE-Dextran protocol while
Lipofectamine 2000 was used to transfect PC12 cells. Cell lysates were
generated 48 h after transfection as described [11]and the protein concentration
of clarified lysates determined using the DC protein assay.
2.9. Immunoprecipitations
Immunoprecipitations were carried out on equal amounts of total lysate
protein as previously described [11]. Monoclonal antibodies were precipitated
with 15 μl of Pansorbin and 15 μl of Gamma Bind Sepharose (Amersham
Biosciences) while polyclonals were precipitated with 20 μl of Pansorbin.
Washed pellets were re-suspended in 1× SDS-PAGE sample buffer, containing
100 mM DTT, and heated at 75 °C for 5 min.
2.10. Western blotting
Protein samples separated by SDS-polyacrylamide gel electrophoresis were
transferred onto Poly-Vinyl Di-Flouridine (PVDF) membranes (Bio-Rad) using
a semi-dry transfer apparatus. Blotto (10% powdered milk in PBS/Tween) was
employed as a blocking agent with all antibodies except for the anti-
phosphotyrosine and anti-active MAPK/ERK/AKT. For these antibodies, 2%
BSA in 10 mM Tris [pH 7.5], 100 mMNaCl, 0.1% Tween 20 plus 1 mM sodium
orthovanadate was used throughout. Relevant protein bands were detected using
the Western Lightening Chemiluminescence kit (Perkin-Elmer).
2.11. Neurite response assay
Neurite response assays were performed in poly-D-lysine coated 24 well
dishes. Cells were plated at 2000–3000 cells per well. Four separate treatment
conditions were employed: (i) no Dox/no treatment; (ii) no Dox/+NGF; (iii)
+Dox/−NGF; (iv) +Dox/+NGF. Cells were stimulated with Doxycycline
(2 μg/ml) or vehicle (DMSO) for 48 h after which they were stimulated with
NGF (20 ng/ml) for an additional 4 days. Fresh Doxycycline (2 μg/ml) and
NGF (20 ng/ml) was added daily. Neurite response was defined as cells with
processes greater than two cell body diameters in length. In all experiments
(n=3), 10 separate frames (550–800 cells) were counted per condition and
converted into percentages. The levels of Dox-induced FRS3 expression was
confirmed by Western blot analysis of whole cell lysates upon termination of
the assay.
2.12. In vitro binding assays
Glutathione-S-transferase fusion proteins (GST-Cks1, GST-Cks2 and GST-
p13suc1) were expressed in E. coli strain BL21-DE3 RIL cells (Stratagene). The
cells were lysed by sonication in PBS, pH 7.5 containing 2% Triton X-100,
10 μg/ml leupeptin, 10 μg/ml aprotinin, 10 μg/ ml pepstatin, 1 mM EDTA and
1 mM PMSF and centrifuged at 20,000×g to remove insoluble debris. Fusion
proteins were purified on glutathione–sepharose beads (Pharmacia) and
resuspended in lysis buffer containing 1 mM DTT. Fusion proteins were
quantified either by direct comparison to known amounts of BSA by SDS-
PAGE or by elution from the glutathione–Sepharose with 50 mM reduced
glutathione in 25 mM Tris–Cl, pH 7.5 with 137 mM NaCl, 1 mM EDTA and
10% glycerol, followed by dialysis against elution buffer without glutathione
and quantified by direct protein assay. Insect cells expressing myc-tagged FRS2
and FRS3 were disrupted in NP-40 lysis buffer (see above) and assessed for
protein. Pulldown experiments were performed using 1 μg of GST-fusion
protein, comparable levels of insect cell lysates expressing FRS2, FRS3, FRS2
(PTB)FRS3, FRS3(PTB)FRS2, IRS2FRS2 and IRS2FRS3 and glutathione
sepharose. Complexes were isolated by centrifugation, washed with PBS-Triton
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blotting using the anti-myc antibody 9E10.
3. Results
3.1. FRS3 binds the Trk family of neurotrophin receptors
The PTB domain of FRS3 has been reported to interact
directly with the TrkA receptor [21]. To determine the possibility
of differential interactions with the other members of the Trk
family, we assayed for differences in interaction with TrkA,
TrkB and TrkC using the yeast two-hybrid system. However, as
shown in Fig. 1B, we found that full-length FRS3 bound
comparably to the intracellular domains (ICDs) of TrkA, TrkB
and TrkC. FRS2 binding to all three Trks served as a positive
control [11].
FRS2 binds to rat TrkA at phosphotyrosine residue 499 and
requires integrity of the preceding amino acids, IMENPXY [11].
Therefore, we wished to determine if FRS3 bound the same
residue in rat TrkA and if this interaction also required integrity
of the NPQYmotif. Full-length FRS2 and FRS3 were expressedFig. 2. FRS3 is tyrosine phosphorylated by TrkA, TrkB, and TrkC. (A) Myc-tagged F
or empty pCMX vector (TrkA-lanes). Cells co-transfected with HA-TrkA and pEGFP
with 100 ng/ml NGF for 10 min before lysis. Twenty micrograms of total cell lysate w
the anti-pTyr (RC20). The blot was stripped and re-probed with 9E10 to confirm leve
either HA-tagged TrkA, TrkB or TrkC or kinase dead TrkA (K547A). Cells were stim
were immunoprecipitated and the blots probed with the indicated antibodies, anti-pTin yeast along with either wild-type TrkA, and a series of TrkA
mutants (Fig. 1C) including: (i) S3, a 493ΔIMENP497 deletion
mutant that disrupts the NPQY499 motif required for FRS2
binding [11], (ii) S8, a Y499F substitution that also abrogates
FRS2 binding, [11,27], (iii) S9, a Y794F substitution that
disrupts PLC-γ1 binding [27] and (iv) S11b, a kinase inactive
K547A mutant. As shown in Fig. 1D, both FRS3 and FRS2
interact with wild type Trk and TrkA S9, but not with TrkA S11b
or TrkA S8. These results indicate that FRS3 binds to TrkA
following phosphorylation of tyrosine 499. Unlike FRS2,
however, FRS3 retains binding to the TrkA S3 deletion mutant,
suggesting a subtle difference in how these adapters interact
with the ICD of the Trk receptors. Expression of all four mutant
TrkA constructs was verified by Western blotting (Fig. 1E).
3.2. FRS3 is tyrosine phosphorylated by FGF, NGF, NT-3 and
BDNF but not EGF
It has previously been demonstrated that FRS3 is tyrosine
phosphorylated in response to FGF in transfected fibroblasts
[16]; however, whether this is also true for neurotrophinRS2 and FRS3 were expressed in COS-7 cells along with either HA-tagged TrkA
-C1 served as a negative control for FRS2 and FRS3. The cells were stimulated
ere immunoprecipitated with the anti-myc antibody (9E10) and blots probed with
ls of FRS expression. (B) Myc-tagged FRS3 was co-expressed in COS cells with
ulated with the appropriate ligand (100 ng/ml, 5 min) prior to cell lysis. Lysates
yr (1:2500), anti-myc (1:10,000) and anti-HA (1:5000).
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expressed FRS3/myc in COS-7 cells in the absence and presence
of co-transfected TrkA. As a positive control, FRS2 was also
assayed. As shown in Fig. 2A, FRS3 and FRS2 are tyrosine
phosphorylated in response to NGF only when co-expressed
with TrkA, suggesting that both FRS proteins are targets of the
Trk kinase. Over-expressed FRS2 and FRS3 both run as a
doublet on SDS-PAGE, the reasons for which are not entirely
clear. Stripping and re-probing the blot reveals similar levels of
FRS2 or FRS3 expression in the absence or presence of TrkA,Fig. 3. FRS3 is tyrosine phosphorylated by NGF, NT3, BDNF and bFGF, but not EG
untreated or induced with Dox (2 μg/ml) and lysates probed for FRS3 expression and
of FRS3. (C, D) E15 primary mouse cortical neurons were untreated or stimulate
immunoprecipitated with anti-Trk, FGFR1, EGFR and FRS3 antibodies and Wester
probed as indicated with anti-myc, anti-Trk and anti-FRS3 antibodies (1:10,000).however, FRS3 is expressed at much higher absolute levels as
compared to FRS2. This difference in expression levels is
independent of the cell line and the expression construct that is
used. In addition, FRS2 consistently migrates slower on SDS-
PAGE than FRS3 despite the 2 proteins having similar predicted
molecular weights. This most likely reflects the fact that FRS2 is
phosphorylated on multiple serine/threonine residues [19].
Our observation that FRS3 interacts with all three Trk RTKs
prompted us to examine the ability of these kinases to
phosphorylate FRS3. As shown in Fig. 2B, FRS3 is tyrosineF, in PC12 cells and primary cortical neurons. (A, B) PC12-FRS3-23 cells were
/or NGF, EGF and bFGF (100 ng/ml, 5 min) stimulated tyrosine phosphorylation
d with NGF, BDNF, NT-3, EGF or bFGF (100 ng/ml, 5 min). Lysates were
ns were blotted with anti-pTyr antibodies (1:2500). Blots were stripped and re-
Fig. 4. TrkA Stimulates FRS3 Co-immunoprecipitation with Grb2 and Shp2. (A)
PC12-FRS3-23 cells were assayed for FRS3 co-immunoprecipitation of
endogenous Shp2 and Grb2. (B) Schematic of FRS3 mutants. (C) HA-tagged
wt TrkA (lanes 1–8) or kinase dead TrkA (S11B, lane 9) was co-expressed with
either Myc-tagged wild-type FRS3 (lanes 1, 9), FRS3-PTB domain (lane 3),
FRS3-3A mutant (lane 4), FRS3-4A mutant (lane 5), FRS3-Y417A (lane 6),
FRS3-Y455A (lane 7) or the FRS3-2A mutant (lane 8) in COS-7 cells. The cells
were stimulated with NGF for 5 min following which they were processed for
immunoprecipitation with 9E10 as described in Materials and methods.
Immunoprecipitates were divided into two equal halves and blotted with either
anti-Shp2 (upper panel, 1:2500) or anti-Grb2 (middle panel, 1:2500) antibodies.
The blot was stripped and re-probed with 9E10 (lower panels, 1:10,000). Arrows
indicate the positions of Shp2, Grb2, and FRS3.
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cognate receptors for these ligands TrkA, TrkB and TrkC,
respectively, are co-expressed. Kinase inactive receptors are
unable to stimulate tyrosine phosphorylation of FRS3 (Fig. 2B
and data not shown). Thus, FRS3, like FRS2, appears to be
tyrosine phosphorylated by all members of the Trk family.
To examine the relationship between FRS3 and TrkA further,
we generated three independent lines of PC12 cells over-
expressing FRS3/myc under the control of a tetracycline indu-
cible promoter. As shown in Fig. 3A, three cell lines (FRS3-23,
FRS3-27, and FRS3-48) were selected based on tight induction
of FRS3/myc expression in response to 48 h of Doxycycline
(2 μg/ml) treatment (Fig. 3A, upper panel). FRS3 was stably
expressed even after 8 days of Dox stimulation (lower panel). Of
note, the FRS3-23 cell line expressed much higher levels of
FRS3/myc than clone 27 or 48. PC12 cells also express receptors
for epidermal growth factor (EGF); however, as shown in Fig.
3B, only NGF and FGF stimulate FRS3 tyrosine phosphoryla-
tion in Dox-induced cells. These observations are consistent
with the data presented in Fig. 2 and support a model of RTK
specificity in the binding and tyrosine phosphorylation of FRS3.
To address the phosphorylation of endogenous FRS3 in
primary neurons, we assayed mouse cortical neurons where
FRS2 is tyrosine phosphorylated in response to BDNF and NT-3
[28,29]. To facilitate this analysis, a polyclonal antibody was
generated using an FRS3-specific peptide. Cortical neurons were
isolated from E15 mouse embryos, cultured for 2–4 days in vitro
and stimulated with NGF, BDNF or NT-3 for five min, then lysed
and immunoprecipitated with anti-Trk or anti-FRS3 antibodies
followed by blotting with an anti-phosphotyrosine antibody. As
demonstrated in Fig. 3C, endogenous TrkB, TrkC and FRS3 are
tyrosine phosphorylated in cortical neurons in response to BDNF
and NT-3 stimulation. Stripping and re-probing the blots with
anti-Trk or anti-FRS3 antibodies confirms the identity of the
phosphotyrosine bands. Importantly, these observations demon-
strate that endogenous FRS3 is a target of the Trk kinases in
embryonic cortical neurons. Lastly, we also addressed the
specificity of growth factor-induced tyrosine phosphorylation
of FRS3. Similar to our results obtained in PC12 cells (Fig. 3B),
neurotrophin stimulation (BDNF), FGF and EGF all induce the
tyrosine phosphorylation of their cognate RTKs while only
BDNF and FGF, but not EGF, induce the tyrosine phosphory-
lation of FRS3 in embryonic cortical neurons (Fig. 3D).
3.3. Neurotrophic activation of TrkA stimulates the
co-immunoprecipitation of FRS3 with Grb2 and Shp2
Based on the amino acid sequence of FRS3 (Fig. 1A) [17],
and previous observations with FRS2 [20,30], we predicted that
both Grb2 and Shp2would bind FRS3. As shown in Fig. 4A, this
assumption is correct as both Shp2 and Grb2 co-immunopreci-
pitated with FRS3 in a NGF-dependent fashion. To investigate
this in further detail, we constructed a series of FRS3 mutants in
which the tyrosine residues within each of the consensus binding
motifs were mutated to alanine (Fig. 4B). These were then over-
expressed in COS cells in conjunction with either wild-type
TrkA or kinase dead TrkA S11b, stimulated with NGF, andsubjected to anti-Myc immunoprecipitation. As shown in the
upper panel of Fig. 4C, we observed a strong NGF-dependent
co-immunoprecipitation between wild type FRS3 and Shp2
(lane 2). This interaction was reduced by the single mutations
Y417A and Y455A (lanes 6 and 7), and completely eliminated
when using the isolated FRS3-PTB domain (lane 3), the FRS3-
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Co-immunoprecipitation of Shp2 was not impaired in the FRS3-
3A mutation, which lacks the three Grb2 binding sites (lane 4),
or the 4A mutant (lane 5) which contains only Y417.Fig. 5. IRS2FRS2 and IRS2FRS3 chimerical proteins support insulin-dependent M
integrity of the Grb2 and Shp2 binding sites. (A) nnr5-B5 cells were transfected the
described in Materials and methods and stimulated for the indicated times with 10 μ
described in Materials and methods. Activated MAPK/ERK was determined using th
with the α-MAPK/ERK antibody (1:10,000). Expression of the IRS2 chimeras was
were transfected with a control vector containing only the PTB domain of IRS2, IRS
was assessed after 48 h. (C) Nnr5-B5 cells stimulated with 10 μg/ml insulin or 100
Immune complexes were analyzed for TrkA with the anti-HA antibody, 3F10 (1:50
Y323A) and IRS2/FRS3-2A (Y418A; Y456A), serum starved for 24–48 h and stim
detected as above and expression of IRS2FRS3 mutants was determined using an a
IRS2FRS3-3A were stimulated with insulin as described in (A). The cells were asseWe also observed Grb2 to co-immunoprecipitate with FRS3
cells expressing wild-type, but not kinase dead, TrkA (Fig. 4C,
middle panel; lanes 2 and 9). This co-immunoprecipitation was
not observed with FRS3 containing triple alanine substitutionsAPK/ERK phosphorylation and neurite outgrowth and is dependent upon the
chimerical proteins IRS2/FRS2 and IRS2/FRS3 serum starved for 24–48 h as
g/ml insulin. Lysates were prepared and analyzed for phospho-MAPK/ERK as
e phospho-MAPK/ERK antibody (1:10,000) and the blots stripped and reprobed
determined using α-FRS2 and α-FRS3 antibodies (1:3000). (B) Nnr5-B5 cells
2FRS2 or IRS2FRS3, and stimulated with 10 μg/ml insulin. Neurite outgrowth
ng/ml NGF were immunoprecipitated with an anti-phosphotyrosine antibody.
00). (D) Nnr5-B5 cells were transfected with IRS2/FRS3-3A (Y192A; Y288A;
ulated with 10 μg/ml insulin for the indicated times. Phospho-MAPK/ERK was
nti-FRS3 antibody (1:3000). (E) Nnr5-B5 cells expressing IRS2FRS3-2A and
ssed for neurite outgrowth after 48 h.
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4 and 5). Co-immunoprecipitation was observed between Grb2
and FRS3 with single mutations in the Shp2 binding sites
(Y417A, Y455A, lanes 6, 7) as well as the double 2A mutant
(lanes 8). Neither Shp2 nor Grb2 were immunoprecipitated with
the FRS3 PTB domain alone (lane 3). The lowest panel of Fig.
4C verifies comparable FRS3 expression in each transfection as
well as high levels of the FRS3 PTB domain.
3.4. A chimerical insulin receptor substrate (IRS) 2/FRS3
adapter supports insulin-dependent MAPK/ERK activation and
neuritogenesis and is dependent upon the integrity of the Grb2
and Shp2 binding sites of FRS3
Although the results above suggest a degree of overlap in
FRS2 and FRS3 signaling, we wanted to determine whether
FRS3, upon activation, could induce prolonged MAPK/ERK
activation and neurite outgrowth independently of those
activated by endogenous FRS2 in PC12 cells. To detect
potential activation of these pathways by FRS3, we generated
a chimeric adapter in which the PTB domain of FRS3 was
replaced with the PH/PTB domains of IRS2. This approach was
employed previously [14] to demonstrate MAPK/ERK activa-
tion by FRS2 in response to insulin. Insulin typically stimulates
lower, transient levels of MAPK/ERK activity and is mitogenic
for PC12 cells. TrkA expressing nnr5 cells (B5) were transiently
transfected with the IRS2/FRS2 or IRS2/FRS3 chimeras and
assayed for insulin-induced MAPK/ERK activation as well as
changes in differentiation/neurite outgrowth. To facilitate theseFig. 6. FRS3 over-expression does not potentiate NGF-induced neurite outgrowth in
PC12 cells lines were subjected to one of several treatments (in separate wells): (1) −D
neurite formation. Induction of FRS3 expression and neurite outgrowth was as descr
total of 6 days and NGF for 4 days. The concentration of Dox was 2 μg/ml and NGFw
500–850 cells counted in 10 frames. Error bars are the standard deviation from the m
response assay in (A) was terminated and the cells lysed and assessed for FRS3 expstudies, transfected cells were serum-starved for at least 24 h
before stimulation with 10 μg/ml insulin [14]. We employed
nnr5-B5 cells for these studies [13] as we found these cells to be
highly transfectable and to display a high level of neurite
outgrowth. A rapid (10 min) and sustained (12 h) increase in
insulin-dependent MAPK/ERK phosphorylation was observed
in both IRS2/FRS2 and IRS2/FRS3 expressing cells, a
phenomenon not observed in control nnr5-B5 cells expressing
only the IRS2 PTB and PH domains (Fig. 5A). For reasons that
are not clear, we consistently observed higher expression of
IRS2/FRS2 than that of IRS2/FRS3 (Fig. 5A, lower panel). In
agreement with the results in Fig. 5A, nnr5-B5 cells expressing
both IRS2/FRS2 and IRS2/FRS3 expressing cells undergo
insulin-dependent neurite outgrowth (Fig. 5B). However,
process formation in IRS2/FRS3 expressing cells is more
robust than that in IRS2/FRS2 expressing cells despite similar
levels of MAPK/ERK phosphorylation (Fig. 5B). TrkA
phosphorylation occurred only in response to NGF indicating
no indirect insulin-mediated activation of TrkA (Fig. 5C).
The ability of FRS2 to facilitate FGF-dependent neurite
outgrowth relies on the recruitment and activation of Shp2 [30].
Thus, we next assessed the relative importance of Grb2 and
Shp2 binding to FRS3 in promoting MAPK/ERK activation and
neurite outgrowth. Thus, IRS2/FRS3 chimeras with mutations
at either the three Grb2 (Y194A, Y288A and Y323A) or the two
Shp2 (Y418A and Y456A) binding sites were assayed for their
ability to support insulin-dependent MAPK/ERK activation and
neurite outgrowth in nnr5-B5 cells. No increase in insulin-
dependent activation of MAPK/ERK, compared with thePC12 cells. (A) Wild-type PC12 cells and three lines of FRS3 over-expressing
ox/−NGF, (2) −Dox/+NGF, (3) +Dox/−NGF, (4) +Dox/+NGF and assessed for
ibed in Materials and methods. The cells were incubated with doxycycline for a
as 20 ng/ml. The percentage of neurite positive cells is represented as the mean of
ean. Similar results were obtained in three independent assays. (B) The neurite
ression (40 μg of total cell lysates).
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either mutant even after 24 h of insulin treatment (Fig. 5D, left
panel). Similar levels of expression were observed for both
mutants (Fig. 5D, right panel). Accordingly, we also failed to
observe any effect of insulin on neurite outgrowth in either of
the IRS2/FRS3 mutant expressing nnr5-B5 cells (Fig. 5E).
3.5. Over-expression of wild type FRS3 does not enhance
NGF-dependent neuritogenesis
Over-expression of FRS2 in PC12 cells augments growth
factor induced neurite outgrowth more than two-fold greater
than that observed in the absence of growth factor [11,30]. In
addition, FRS2 over-expression facilitates NGF-induced mitotic
arrest [15]. These effects are most likely a consequence of aFig. 7. FRS3 Over-expression Does not Potentiate NGF-Induced MAPK/ERK Phosph
27 and 48) were exposed to one of six treatments: (1) −Dox/−NGF, (2) −Dox/+NG
adding NGF (2 ng/ml). For each condition, 15 μg of total cell lysate was assayed w
striped and re-probed with anti-MAPK/ERK1/2 antibodies (lower panel, 1:10,000). (B
with 9E10 (1:10,000). Similar results were obtained in three independent assays.higher level of MAPK/ERK activity observed upon over-
expression of FRS2 [30]. Since the chimeric IRS2/FRS3
adapter stimulates prolonged MAPK/ERK activation in re-
sponse to insulin, we determined if over-expression of FRS3
would similarly augment neurite outgrowth in PC12 cells.
Our PC12-FRS3 over-expressing lines were either treated
with Doxycycline (2 μg/ml; 48 h), to induce FRS3 expression,
or left untreated and stimulated with either vehicle or 20 ng/ml
NGF. Fresh Dox and NGF were added daily. After 4 days of
NGF treatment, neurite extension was scored by counting the
percentage of cells containing neurites longer than two cell
bodies. Ten frames (550–800 cells) from duplicate samples
were scored. As shown in Fig. 6A, the percentage of NGF
responsive PC12 cells, irrespective of Dox treatment, was
approx. 10–12%. While the mean percentage of NGF-orylation. (A)Wild-type and three lines of FRS3 over-expressing PC12 cells (23,
F, (3) +Dox/−NGF (4) +Dox/+NGF. Dox (2 μg/ml) was added for 48 h before
ith anti-active MAPK/ERK1/2 antibodies (upper panel, 1:10,000). Blots were
) Dox-induced FRS3 expression was assessed in cell lysates (30 μg) by blotting
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absence of Dox, there was no change in the percent responsive
cells in the presence of Dox stimulation. Dox-induced
expression of FRS3 was confirmed by Western blot analysis
in a parallel set of plates at the end of the assay (Fig. 6B).
Similar results were obtained in 3 independent assays.
3.6. Over-expression of FRS3 does not enhance NGF-induced
MAPK/ERK/MAPK/ERK or Akt activation
While FRS3 expression in PC12 cells did not increase the
percentage of neurite bearing cells in response to NGF, we
reasoned that if NGF-stimulation, via intrinsic pathways,
already met threshold response levels, FRS3 over-expression
may not significantly increase the absolute levels of detection.
To address this possibility, we asked whether over-expression of
FRS3 altered detectable levels of NGF-dependent MAPK/ERK
or Akt activation. Over-expressing cell lines were either left
untreated or treated with Doxycycline (2 μg/ml; 48 h), to induce
FRS3 expression, and stimulated with either vehicle or NGF
(2 ng/ml) for 15 min and 2 h. As shown in Fig. 7A, NGF
stimulated a significant level of MAPK/ERK phosphorylation
at 15min and 2 h in parental PC12 cells that was not significantly
affected by treatment with Dox (Fig. 7B). All three Dox-
inducible cell lines exhibited NGF-dependent MAPK/ERK
phosphorylation, however, we found no statistical difference in
the absolute level of phospho-MAPK/ERK, at either time pointFig. 8. FRS3 Over-expression Does not Potentiate NGF-Induced AKT Phosphorylatio
were exposed to one of six treatments: (1) −Dox/−NGF, (2) −Dox/+NGF, (3) +Dox/−N
NGF. For each condition, 35 μg of total cell lysate was assayed with anti-AKT (Ser473)
(middle panel, 1:1000). Dox-induced FRS3 expression was assayed in cell lysates (40 μ(N=3), between pairs of untreated and Dox treated cultures
(Fig. 7A). Similarly, no statistical difference in phospho-
MAPK/ERK levels was seen when cells were incubated with
NGF for 6 and 24 h (data not shown). Stripping the blots and re-
probing with anti-MAPK/ERK demonstrated comparable levels
of protein loading per lane. Importantly, the failure of Dox to
influence NGF-dependent MAPK/ERK activity was not a
consequence of lack of Dox-induced FRS3 expression in all
lines (23, 27 and 48) (Fig. 7B).
Using the same approach, we assayed for potential Dox/
FRS3-dependent changes in levels of phosphorylated Akt
following 30 and 60 min of NGF (5 ng/ml) stimulation. As
shown in Fig. 8, Dox had no effect on the apparent levels of
NGF-induced Akt phosphorylation at Ser473 in parental PC12
cells. Similarly, in all three FRS3 clones, FRS3 over-expression
did not increase the NGF-dependent levels of phosphorylated
Akt, despite similar levels of protein loading per lane (n=3).
Again, densitometric analysis of the levels of phosphorylated
Akt between the Dox treated and untreated pairs revealed no
statistical differences.
3.7. FRS3 does not interact with yeast p13suc1 or the
orthologous mammalian Cks proteins
FRS2 was originally identified by its ability to bind the yeast
cell cycle regulatory protein, p13Suc1 [20,28,31], themammalian
orthologues of which are Cks1 and Cks2 [32]. Cks1 and Cks2n. Wild-type and three lines of FRS3 over-expressing PC12 cells (23, 27 and 48)
GF (4) +Dox/+NGF. Dox (2 μg/ml) was added for 48 h prior to addition of 5 ng/ml
antibodies (upper panel, 1:1000). Blots were striped and re-probed for total AKT
g) by blotting with 9E10. Similar results were obtained in three independent assays.
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identity with p13Suc1 (Fig. 9A). Both Cks1 and Cks2 bind to
the N-terminal region of FRS2 [33] with the binding site
spanning the myristolation site into the PTB domain [33].
Previously, it had been reported that FRS3 does not bind
p13Suc1 [16], raising the possibility that FRS3 similarly does
not interact with Cks1 or Cks2.
To address the binding capacity of FRS2 and FRS3 with
Cks1 and 2, we used the yeast two-hybrid system. Yeast were
co-transformed with full-length FRS3 or FRS2 fused to the
Gal4 DNA binding domain along with Cks1, Cks2 or the
intracellular domain (ICD) of TrkA (as a positive control) fused
to the Gal4 transactivation domain (TAD). We also included a
Gal4 TAD-p13suc1 fusion as a control. Yeast were transfected
with the appropriate vectors and assessed for protein expression.
All proteins were expressed to varying degrees in yeast (Fig.
9B). Colonies were plated on selective HALT plates to assessFig. 9. FRS3 does not interact with Yeast p13suc1 or Mammalian Cks Proteins. (A
Residues shaded in black are identical while grey residues are conservative substit
expression of the Gal4-DBD and corresponding FRS2/3 fusions as well as the Gal4-T
anti-HA (3F10, 1:5000) antibodies, respectively. (C) Binding of full-length FRS2 a
Cks1, Cks2 and TrkA ICD (all expressed as Gal4 Trans-activation domain [TAD
−tryptophan selective media (see Materials and methods). After 4 days growth, the c
media, plus 10 mM 3-AT, to test for protein–protein interactions. The ‘−’ symbol inprotein interaction. Neither FRS2 nor FRS3 interacted with the
activation domain of Gal4 alone, while both interacted with the
positive control, TrkA (Fig. 9C). Growth on HALT plates was
observed for FRS2 and p13suc1, Cks1 and Cks2 indicating a
positive interaction. In contrast, we observed no growth when
FRS2 was replaced with FRS3, indicating a lack of interaction
(Fig. 9C).
We also performed an in vitro binding assay using p13suc1,
Cks1 and Cks2 fused to glutathione-S-transferase (GST). The
fusion proteins were expressed in E. coli, and used to
precipitate myc tagged FRS2 and FRS3 over-expressed in
baculovirus infected Sf9 insect cells. All three GST fusion
proteins effectively precipitated FRS2 but not FRS3 (Fig. 10A,
lanes 1–4 and 6–9). Again, FRS2 and FRS3 migrate at
different rates on SDS-PAGE (Fig. 10A, compare lanes 5 and
10). These data indicate that there are sufficient structural
dissimilarities in the N-terminal regions of FRS2 and FRS3 to) Sequence alignment of p13Suc1 from S. pombe versus mouse Cks1 and Ck2.
utions. (B) Lysates prepared from colonies growth in SD-LT were assayed for
AD and corresponding p13suc1, Cks fusions using anti-Gal4 DBD (1:5000) and
nd FRS3 (expressed as Gal4 DNA binding domain [DBD] fusions) to p13Suc1,
] fusions). Yeast (AH109) were transformed, plated onto minus −leucine and
ells were replated on −histidine, −adenine, −leucine, and −tryptophan selective
dicates control co-transformations with empty vectors.
Fig. 10. Cks1 and Cks2 do not interact with the PTB Domain of IRS2. (A) Glutathione-S-transferase (GST) fusions of Cks1, Cks2 and p13suc1 were expressed and
purified as described in Materials and methods. Bacculoviruses were generated with myc-tagged FRS2 and FRS3 and used to infect T. ni insects cells. Pulldown assays
from insect cell lysates were performed as described in Materials and methods. Lanes 5 and 10 represent the assay input. (B) Bacculoviruses were generated with myc-
tagged FRS3(PTB)FRS2, FRS2(PTB)FRS3 and IRS2FRS2 and used to infect insect cells. Pulldown assays were as described (Materials and methods). Lanes 5, 10
and 15 represent assay input. Proteins were detected using 9E10.
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proteins.
Our data suggest that the Cks1/FRS2 interaction is not
essential for the induction of cell cycle arrest and differentiation
in nnr5-B5. Indeed, the Cks1/FRS2 interaction was proposed to
play a regulatory role in FGF-mediated mitogenesis [33]. To test
this hypothesis we performed an additional in vitro binding
assay using GST-Cks1/2 and IRS2/FRS2 expressed in insect
cells to determine whether Cks1/2 could interact with the PH-
PTB domain of the IRS2/FRS2 chimera. The results indicate
that neither Cks1 nor Cks2 are able to precipitate IRS2/FRS2
(Fig. 10B, lower panel, lanes 1–4) indicating that IRS2/FRS2
and IRS2/FRS3 mediated insulin-dependent neurite outgrowth
in nnr5-B5 cells occurs independently of Cks1/2 binding. We
also looked at the interaction of Cks1/2 with chimerical FRS2
and FRS3 proteins in which we had swapped their respective
PTB domains. Predictably, the FRS3(PTB)/FRS2 chimera was
incapable of binding either Cks1 or Cks2 (Fig. 10B, lower
panel, lanes 6–9); however, we were surprised to observe a
similar result with the FRS2(PTB)/FRS3 chimera (Fig. 10B,
lower panel, lanes 11–14). These data suggest that either
structural determinants beyond the PTB domain are also
important in binding of Cks1/2 to FRS2 or that the structure
of the FRS2/FRS3 chimera is inhibitory to Cks binding.Moreover, the fact that p13suc1 binds to IRS2/FRS2 and FRS3
(PTB)/FRS2, but not to FRS2(PTB)/FRS3, suggests that
p13suc1 binds FRS2 carboxy-terminal to the PTB domain.
4. Discussion
We present four lines of evidence supporting a role for the
FRS3 adapter in neurotrophic signal transduction. First, FRS3
binds all three members of the Trk family of RTKs in a
phosphotyrosine-dependent manner. Secondly, FRS3 is tyrosine
phosphorylated in response to neurotrophic or bFGF but not
EGF stimulation. Thirdly, upon tyrosine phosphorylation, FRS3
recruits Grb2 and Shp2, two known mediators of neurotrophic
signaling downstream of the Trk receptors. Finally, a chimeric
FRS3 protein in which the PTB domain was replaced with the
PH and PTB domains of the Insulin Receptor Substrate 2 (IRS2)
induced prolonged MAPK/ERK activity and neurite outgrowth
in PC12 cells in response to insulin. This latter result is in
agreement with those of Gotoh et al. [19] who showed that
ectopic expression of FRS3 in FRS2 null fibroblasts recon-
stituted FGF-dependent MAPK/ERK phosphorylation. We
have extended this observation to show that FRS3, similar to
FRS2, is capable of stimulating prolonged MAPK/ERK activity
and neurite outgrowth in PC12 cells, albeit using a chimerical
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originally postulated that FRS3 over-expression in PC12 cells
might significantly enhance NGF-dependent neurite outgrowth
and MAPK/ERK-1/2 phosphorylation relative to controls,
comparable to the effects of FRS2 [20], this was not observed
even when cells were assayed at low doses of NGF (2 ng/ml).
This suggests that FRS3 over-expression uses different
mechanisms to support ligand-dependent activation of
MAPK/ERK in PC12 cells relative to FRS2.
While both FRS2 and FRS3 are tyrosine phosphorylated and
bind Grb2 and Shp2 in response to NGF, we have observed
differences that may directly affect the signaling events
mediated by these two adapters. For example, both FRS2 and
FRS3 bind TrkA at phosphotyrosine 499, FRS2 binds with a
broader footprint as reflected in its decreased ability to
interact with the S3 mutant in which the immediately upstream
493IMENP497 pentapeptide is deleted [11]. Conversely, FRS3
still binds the TrkA-S3 mutant suggesting a different binding
conformation and/or interaction of FRS3 with TrkA as
compared to FRS2. A similar observation has been made for
FRS2 and FRS3 binding to the FGFR1 where FRS2 binds to a
juxtamembrane region encompassing AAs 401–434 while
FRS3 binding requires an additional C-terminal 17 amino
acids, amino acids 401–451 [16].
Similar to FRS2 [20,30], Grb2 and Shp2 also have
important implications for FRS3 signaling; however, our
data suggest subtle differences between FRS2 and FRS3 with
respect to Grb2 and Shp2 binding, which may have effects on
downstream signaling pathways. In this respect, FRS2 and
FRS3 share three conserved Grb2 (Y192, 287 and 322 in
FRS3 and Y196, 306 and 349 in FRS2) and two conserved
Shp2 binding sites (Y436 and 471 in FRS2 and Y418 and 456
in FRS3), with FRS2 containing an additional Grb2 binding
site at Y392 [20]. Elimination of all Grb2 sites in FRS3
abrogates Grb2 co-immunoprecipitation with FRS3 indicating
that Grb2 is only recruited into a signaling complex directly.
In contrast, Grb2 is recruited to FRS2 by direct binding as
well as via binding to Shp2 [30]. While the direct implications
of these differences are not immediately apparent, it may
account for the observation that FRS2, but not FRS3, over-
expression augments NGF-induced MAPK/ERK activation in
PC12 cells.
Another difference between FRS2 and FRS3 concerns the
ability of FRS2 but not FRS3 to bind Cks1 and Cks2, the
mammalian orthologs of the yeast cyclin-dependent kinase
binding protein p13suc1. Binding of FRS2 to p13suc1 has been
known for some time as the protein was originally identified
by precipitation with p13suc1-agarose [28]. The binding of
Cks1 and Cks2 to FRS2 is mediated through an N-terminal
motif spanning the myristoylation site and extending into the
PTB domain of FRS2 [33]. It was proposed that Cks1 binds to
unphosphorylated FRS2 and is displaced upon FGFR-
mediated phosphorylation [33]. Displacement of Cks1, and
its re-distribution into the nucleus, allows for the degradation
of p27Kip1 thereby permitting the cells to complete the G1/S
transition [33]. Thus, the evidence suggests that the Cks1/
FRS2 interaction is an important regulator of FGF-mediatedmitogenesis. Our data with the IRS2 chimeras suggest that the
Cks1/FRS2 interaction is not obligatory to induce growth
arrest and neurite outgrowth in nnr5-B5 cells. Indeed, the IRS2
PTB domain failed to recruit Cks1/2 in vitro. Moreover, FRS3
does not bind Cks1/2 but expression of FRS3 reconstitutes
FGF-dependent MAPK/ERK activation in FRS2−/− fibroblasts
[19].
Previous studies have shown that differentiation of PC12
cells may be induced by over-expression of signaling molecules
resulting in prolonged MAPK/ERK activity (v-src [34], ras
[35], the EGFR [36] and p21 [37]). In spite of this, it is unlikely
that our observations with IRS2/FRS3 reflect an over-
expression artifact. For instance, neurite outgrowth is dependent
upon insulin, in keeping with the chimeric nature of the
proteins. Moreover, the response is not commensurate with the
level of expression, since IRS2/FRS3 is expressed to a lesser
extent than IRS2/FRS2 yet mediated a stronger cellular
response. Rather, these studies provide a platform whereby
the functional role of endogenous FRS3 during neuronal
development can be delineated in either primary neurons or
genetically engineered mouse models.
The differences in the spatio-temporal expression of FRS2
and FRS3 in embryonic development suggests that these
proteins serve different roles in growth and development
[18,19]. In mitotic cells, phosphorylation of FRS2, by FGFR1,
promotes the dissociation and nuclear re-distribution of Cks1
allowing the formation of a Cks1/Cdk/Cyclin/p27Kip1 complex
resulting in the subsequent degradation of p27Kip1, release of an
active Cdk/cyclin complex and cell cycle progression [33]. In
this sense, the Cks 1/FRS2 interactionmay provide a mechanism
to regulate FGF-mediated mitogenesis [33]. The regulation of
this process under conditions in which FRS2 supports a
differentiative response is presently not clear.
Despite differences in Cks1 binding, however, FRS2 and
FRS3 seem to perform many complementary functions.
Expression of FRS3 in FRS2−/− mouse fibroblasts for example,
reconstitutes FGF-dependent MAPK/ERK activation [19]. Our
studies clearly show that FRS3 can function to promote neurite
outgrowth. However, over-expression of FRS3 does not
synergistically enhance NGF-dependent neurite outgrowth.
Recently, a possible anti-mitogenic role for FRS3 has been
proposed in that it decreases EGF-induced MAPK/ERK
signaling in the osteosarcoma cell line, Saos-2 [38]. Ongoing
studies will be directed at determining the consequence of over-
expression and/or loss of FRS3 expression on FGF and/or
neurotrophin-induced proliferation/differentiation in primary
neurons and/or in transgenic mice.
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